EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Basophil Activation Test: Bridging Allergy and Oncology for Diagnostic, Therapeutic and Prognostic Applications in AllergoOncology : An EAACI Position Paper

Mariona Pascal iD, Jitesh Chauhan iD, Edward Knol iD, Rodolfo Bianchini iD, Mariana Castells iD, Leticia De Las Vecillas iD, Karin Hartmann iD, Elena Izquierdo iD, Uta Jappe iD, Teodorikez-Wilfox Jimenez-Rodriguez iD, Francesca Levi-Schaffer iD, Cristobalina Mayorga iD und 7 weitere

Allergy · 2025

DOI: 10.1111/all.16607 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Allergy, 2025. Verfasst von Mariona Pascal und 18 weiteren Autor:innen. Beteiligte Einrichtung: Immunology Department, CDB, Hospital Clínic de Barcelona; Institut D'investigació Biomèdica August pi i Sunyer (IDIBAPS), Universitat de Barcelona, B…. Hauptthemen laut MEDLINE: Basophil Degranulation Test, Hypersensitivity, Basophils, Medical Oncology. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Academy of Allergy and Clinical Immunology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The basophil activation test (BAT) is gaining increasing relevance as an ex vivo functional assay in allergy to evaluate IgE‐mediated hypersensitivity reactions to food allergens, venoms, and drugs and to monitor tolerance induction. Establishing universal standard operating protocols has been difficult, due to several challenges including variable activation markers, positive control selection, the need for processing fresh blood samples, and the existence of non‐releasing individuals. In oncology, BAT is also an emerging promising diagnostic and management tool to assess hypersensitivity reactions to biologics and chemotherapy agents, monitor drug tolerance in desensitisation, and predict and address the safety of novel anti‐cancer IgE‐based therapeutics. This position paper highlights the emerging significance of BAT in AllergoOncology, in facilitating therapy monitoring, biomarker discovery, and risk stratification. Capitalising on long‐acquired expertise in the development of BAT for allergy, we propose research directions and routes to clinical applications of this highly promising tool in AllergoOncology. We advocate the need for enhanced focus on addressing standardisation challenges and leveraging outputs for precision medicine. By linking allergy and oncology, the key remaining limitations can be addressed, with the aim of realising the significant promise of BAT as a robust tool to enhance personalised care in allergy and AllergoOncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Basophil Degranulation TestHypersensitivityBasophilsMedical OncologyHumansPrognosisImmunoglobulin EBiomarkersNeoplasms

Stichwörter der Autor:innen

AllergoOncologyallergybasophil activation test (BAT)cancer immunotherapyhypersensitivity reactionsprecision medicine

Substanzen

Immunoglobulin EBiomarkers

Autor:innen und Institutionen

  • Immunology Department, CDB, Hospital Clínic de Barcelona; Institut D'investigació Biomèdica August pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
  • Department of Medicine, Universitat de Barcelona, Barcelona, Spain.
  • RETICS Asma, Reacciones Adversas y alérgicas (ARADYAL) and RICORS Red De Enfermedades Inflamatorias (REI), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
  • School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, St. John's Institute of Dermatology, King's College London, London, UK.
  • Center of Translational Immunology and Dermatology/Allergology, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University Vienna, Vienna, Austria.

ORCID-Profile: Mariona Pascal, Jitesh Chauhan, Edward Knol, Rodolfo Bianchini, Mariana Castells, Leticia De Las Vecillas, Karin Hartmann, Elena Izquierdo, Uta Jappe, Teodorikez-Wilfox Jimenez-Rodriguez, Francesca Levi-Schaffer, Cristobalina Mayorga, Aurélie Poli, Frank Redegeld, Alexandra F Santos, Erika Jensen-Jarolim, Christoph Bergmann, Sophia N Karagiannis, Heather J Bax

Förderung

  • European Academy of Allergy and Clinical Immunology

Zitieren

APA

Pascal, M., Chauhan, J., Knol, E., Bianchini, R., Castells, M., De Las Vecillas, L., Hartmann, K., Izquierdo, E., Jappe, U., Jimenez-Rodriguez, T. W., Levi-Schaffer, F., Mayorga, C., Poli, A., Redegeld, F., Santos, A. F., Jensen-Jarolim, E., Bergmann, C., Karagiannis, S. N., & Bax, H. J. (2025). Basophil Activation Test: Bridging Allergy and Oncology for Diagnostic, Therapeutic and Prognostic Applications in AllergoOncology : An EAACI Position Paper. Allergy. https://doi.org/10.1111/all.16607

Vancouver

Pascal M, Chauhan J, Knol E, Bianchini R, Castells M, De Las Vecillas L, et al. Basophil Activation Test: Bridging Allergy and Oncology for Diagnostic, Therapeutic and Prognostic Applications in AllergoOncology : An EAACI Position Paper. Allergy. 2025. doi:10.1111/all.16607

BibTeX
@article{Pascal2025,
  author = {Pascal, Mariona and Chauhan, Jitesh and Knol, Edward and Bianchini, Rodolfo and Castells, Mariana and De Las Vecillas, Leticia and Hartmann, Karin and Izquierdo, Elena and Jappe, Uta and Jimenez-Rodriguez, Teodorikez-Wilfox and Levi-Schaffer, Francesca and Mayorga, Cristobalina and Poli, Aurélie and Redegeld, Frank and Santos, Alexandra F and Jensen-Jarolim, Erika and Bergmann, Christoph and Karagiannis, Sophia N and Bax, Heather J},
  title = {Basophil Activation Test: Bridging Allergy and Oncology for Diagnostic, Therapeutic and Prognostic Applications in AllergoOncology : An EAACI Position Paper},
  journal = {Allergy},
  year = {2025},
  doi = {10.1111/all.16607}
}
Kostenlos starten →